Molecular Diagnosis Challenges & Solutions. Using Molecular Kits or Laboratory Developed Tests (Home Brew), Emphasis on Validation
|
|
- Myrtle Cummings
- 5 years ago
- Views:
Transcription
1 Using Molecular Kits or Laboratory Developed Tests (Home Brew), Emphasis on Validation Molecular Diagnosis Challenges & Solutions Behzad Poopak, DCLS PhD Tehran Medical Branch- Islamic Azad University 1391
2 Molecular Diagnosis Clinical molecular diagnostics testing: - Oncology - HLA typing - Hematology - Parentage - Inherited diseases - Forensics - Infectious diseases Test types Laboratory-Developed molecular Tests (LDTs) Lab-modified FDA-approved molecular tests FDA-approved molecular tests (exception- Micro) co)
3 Common Platforms in Molecular l Diagnostics i Assays Conventional PCR Realtime PCR Sequencing FISH Microarray
4 Important Topics in Molecular Diagnostics Verification & Validation Proficiency Testing Quality Control A Timely & Accurate Result
5 Principle Requirements of ISO 15189: If in-house procedures are used, they shall be appropriately validated for their intended use and fully documented. The methods and procedures selected for use shall be evaluated and found to give satisfactory results before being used for medical examinations. A review of procedures by the laboratory director or designated person shall be undertaken initially and at defined intervals.
6 The process of implementing a molecular genetic test for diagnostic use Validation determines that we are doing the correct test; verification confirms that we are doing the test correctly.
7 Validation The steps involved in test validation are meant to answer one main question Is a given test ready to be implemented in the clinical laboratory? In order to answer this question, the clinical utility (ie, usefulness) of the test must be established, along with its analytic performance characteristics and limitations.
8 Assay Validation / Evaluation WHO definition: The process of proving that a procedure works as expected and consistently achieves the expected result. CLIA (42 CFR ) and CAP (GEN ) require that laboratories validate the performance of tests before reporting patient results
9 Requirements For Test Validation CLIA requires that each lab establish or verify the performance specifications of moderate- and highcomplexity test systems that are introduced for clinical use. For an FDA-approved test system without any modifications, the system has been validated d by the manufacturer; therefore, the laboratory need only verify (ie, confirm) these performance specifications. In contrast, for a modified FDA-approved test or an LDT, the laboratory must establish the test s performance specifications, including accuracy, precision, reportable range, and reference range.
10 Principle requirements of fiso : The validation shall be as extensive as is necessary to meet the needs of the given application or field of application. The laboratory shall record: - The results obtained, - The procedure used for the validation, & - A statement as to whether the method is fit for the intended use.
11 Some molecular l assays have been commercially produced d and have gone through an FDA 510(k) clearance or PMA (premarket approval) process. These assays are referred to as in vitro diagnostics or IVDs. In contrast, most new molecular diagnostic assays are developed within individual clinical laboratories and are referred to as laboratory-developed tests or LDTs. Many of these clinically important LDTs are unlikely to ever become FDA cleared or approved because low test volumes make it economically unfeasible to go through h the current FDA 510(k) or PMA approval process.
12 Verifying Performance Specifications Applies to unmodified, approved test systems Laboratory must Demonstrate measurement response it can is obtain shown to performance be valid. specifications comparable to the manufacturer before are directly proportional to the concentration reporting patient results of the analyte in the sample. Accuracy Precision Reportable range of test results Verify appropriate reference intervals (normal values) for the laboratory s population Reportable range: The range of values over which the relationship between the instrument, kit, or system s Linearity: The ability of the test to return values that
13 Recommended Approach to Test Validation Validation work has been artificially divided into 3 steps. Step 1: Planning Phase to Define the Requirements of the Test Step 2: Generate Validation Data Step 3: Implement the Test Each successive step should be addressed in sequence and carefully documented
14 Pre-Validation Considerations for the Design of Laboratory Developed Tests Stringent design/analysis of primers and probes Quality and quantity of extracted nucleic acid Appropriate platform for the test Commutable calibrators and controls Optimization of amplification and detection
15 Modified FDA-approved tests or non-fda cleared tests (e.g., Laboratory Developed Test-LDT) Validating Performance Specifications Applies to Laboratory-developed tests Approved tests that have been modified by the laboratory Before reporting patient results, the laboratory must establish performance characteristics for Accuracy Precision Reference and Reportable ranges Analytical sensitivity (LOD) (LOQ) Analytic specificity Interfering substances Diagnostic (Clinical) Validity
16 Validation of a Modified FDA Test Alteration of any process or analyte in an approved test that may affect performance Changes in: type or concentration of specimen used storage specifications extraction method amplification parameters or platforms manufacturer s cut off using the test for another purpose (quantitative vs. qualitative)
17 Clinical (Diagnostic) Validation Address the clinical significance and utility of the test. Diagnose a disease or disease state Confirm the results of another laboratory test, or clinical diagnosis Monitor and assess disease progression, prognosis or resolution Comparing the test to a gold standard Another test (culture, EIA, chemistry test, FISH) Clinical outcome / endpoint (response to therapy) Use Positive and Negative Predictive values Use ethnic variation and geographic distribution Cite references to clinical studies in the literature
18 Validation & Type of Specimens Were validation studies with an adequate number and representative (reasonable) distribution of samples performed for each type of specimen expected for the assay (e.g., blood, fresh/frozen tissue, paraffin embedded tissue, prenatal specimens? Verification and Validation studies should be performed on all types of specimens that the test is used for.
19 Analytical Sensitivity Can Be Done By Control material of known concentration or copy number (calibrators / standards) Dilutions of analyte (microorganism, gene) of known quantity Quantified amount of RNA or DNA
20 Validation of Laboratory Developed Tests, A. Assay Optimization
21 Validation of Laboratory Developed Tests, B. Analytic Validation 1. Accuracy a. Analyze a known sample (either of known concentration or result, or both) and compare the result with that t obtained by a reference ( gold-standard ) method Include specimens from the indicated patient population p (specimens used for validation should reflect anticipated population with regards to sex, age, race etc.) Choose appropriate data analysis techniques Choose appropriate reference methods Choose appropriate comparative methods
22 Validation of Laboratory Developed Tests, B. Analytic Validation 1. Accuracy b. If disease is uncommon, it may be necessary to obtain commercially available reference materials, if they are available. Otherwise, controls may need to be obtained from another laboratory. For sequencing assays, however, the number of possible mutations essentially precludes the use of reference materials.
23 Validation of Laboratory Developed Tests, B. Analytic Validation 1. Accuracy c. Compare results between new method and reference method or method already established in the lab d. The appropriate number of specimens depends on many factors including, but not limited to: Complexity of the assay Relevance of targets/alleles in the intended use population Data analysis schemes Established accuracy of reference methods
24 Validation of Laboratory Developed Tests, B. Analytic Validation 2. Precision (getting the same results with repetition of the assay) Closeness of agreement between independent (repeated) results of measurements obtained under stipulated conditions. Describes the degree of dispersion of the values of repeated measurements form each other.
25 Validation of Laboratory Developed Tests, B. Analytic Validation Elements of precision: Repeatability closeness of agreement between repeated tests of the same sample under the same operating conditions. Performed under the same conditions with multiple replicates, various sample concentrations (QUANTITATIVE), and various patterns of variants (QUALITATIVE). This is referred to as intra- assay variation. Reproducibility closeness of agreement between the results of measurements when operating conditions are varied. All potential sources of variability should be considered. This is referred to as inter-assay variation. Typically, the same material is analyzed by the same protocol on different days, by different operators and with different equipment.
26 Validation of Laboratory Developed Tests, B. Analytic Validation Sources of variability: Instrument Laboratory Operator (most common source of variability) Sample concentration Sample source Reagent lot (second most common source of variability) Run Time of the day Laboratory environment
27 Validation of Laboratory Developed Tests, B. Analytic Validation The laboratory should consider each source of variability that can occur during testing. a. Within run: Run one sample several times in one run b. Between runs: Run one or more samples in several different runs over several days c. Determine the mean, standard deviation and coefficient of variation (standard deviation mean) d. Precision studies should be carried out for the entire assay, as applicable, from extraction and amplification to detection
28 Examples of Precision Evaluation 1. FOR QUANTITATIVE ASSAYS: Take at least 3 sample concentrations (plasma pools or control samples) that cover the clinically important decision levels (e.g. for HCV quantitative assays a low control of~100 IU/mL, a medium of~5000 IU/mL, and a high of ~100,000 IU/mL). Depending on the assay the low concentration replicates can be two to four times the established Level of Detection (LoD), high concentrations should be close to the 99th percentile of tested concentrations/titers.
29 Thank you, any question?
MOLECULAR TESTING: VERIFYING/VALIDATING INSTRUMENTS, REAGENTS AND ASSAYS. Richard L. Hodinka, Ph.D.
MOLECULAR TESTING: VERIFYING/VALIDATING INSTRUMENTS, REAGENTS AND ASSAYS Richard L. Hodinka, Ph.D. University of South Carolina School of Medicine Greenville Greenville Health System, Greenville, SC hodinka@greenvillemed.sc.edu
More informationCurrent Topics in NYS Clinical Laboratory Oversight
June 13, 2018 1 Current Topics in NYS Clinical Laboratory Oversight Derek Symula, Ph.D. and Stephanie Shulman, MPH, MS, MT (ASCP) June 13, 2018 2 (i) Clinical Laboratory Reference System (CLRS) to monitor,
More informationFDA Regulation of Companion Diagnostics
FDA Regulation of Companion Diagnostics Paul Radensky October 11, 2017 Disclosure + Slideset drawn from Part I of presentation made by Janice Hogan, HoganLovells, October 2016 + Updated where appropriate
More informationMolecular Diagnostic Assay Validation Association for Molecular Pathology Clinical Practice Committee, October 2009
Molecular Diagnostic Assay Validation Association for Molecular Pathology Clinical Practice Committee, October 2009 INTRODUCTION The primary goal of method validation in the molecular diagnostics laboratory
More informationGuide to Fulfillment of Validation and Verification of Examination Requirements
DIAGNOSTIC ACCREDITATION PROGRAM College of Physicians and Surgeons of British Columbia 300 669 Howe Street Telephone: 604-733-7758 ext. 2635 Vancouver BC V6C 0B4 Toll Free: 1-800-461-3008 (in BC) www.cpsbc.ca
More informationTechnical Assessment (TA) Summary Form (M00116)
Technical Assessment (TA) Summary Form (M00116) Please complete the following 2 table summarization of the dossier. Table 1. Summary of Evidence Validation Element For each cell below, please provide the
More informationS1725 Method Validation and Verification: Case Studies and Laboratory Challenges
S1725 Method Validation and Verification: Case Studies and Laboratory Challenges James H. Nichols, PhD, D(ABCC) Lauren N. Person, DO, MPH, FCAP Objectives Identify the difference between method validation
More informationAmerican Society of Cytopathology Core Curriculum in Molecular Biology
American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology Chapter 4 Stephanie A. Hamilton, EdD, SCT, MB(ASCP) CM MD Anderson
More informationAgenda. - Introduction Howard Birndorf. - ASR Issues and the Draft ASR FAQ Guidance Patrick Balthrop
- Introduction Howard Birndorf Agenda - ASR Issues and the Draft ASR FAQ Guidance Patrick Balthrop - IVDMIA Issues and the Draft IVDMIA Guidance Randy Scott - Q&A and Discussion All Who Are We? - Emerging
More informationTest Method Validation of In-Vitro Diagnostic Products. Tim Carr QA Manager, Beckman Coulter
Test Method Validation of In-Vitro Diagnostic Products Tim Carr QA Manager, Beckman Coulter IVD Overview What is an In-Vitro Diagnostic Test IVDs are medical devices and accessories Used to perform tests
More informationLaboratory Developed Tests. William Castellani, MD Inter-regional Commissioner Clinical Pathologist, Penn State Hershey Medical Center
Laboratory Developed Tests William Castellani, MD Inter-regional Commissioner Clinical Pathologist, Penn State Hershey Medical Center Objectives Compare and contrast new test validation requirements for
More informationHow to Choose the Right Equipment/Platforms for your Laboratory
How to Choose the Right Equipment/Platforms for your Laboratory (A Public Hospital Laboratory Perspective) Michelle J. Francis Overview Public Hospital Pressures / Challenges Commercial vs In-house assays
More informationCLSI C60: Assay Validation & Post-Validation Monitoring
CLSI C60: Assay Validation & Post-Validation Monitoring Ross J. Molinaro, MT(ASCP), PhD, DABCC, FACB Medical Director Core Laboratory, Emory University Hospital Midtown Emory Clinical Translational Research
More informationGuideline of the Sector Committee Pathology/Neuropathology for the validation of examination methods in Molecular Pathology
Guideline of the Sector Committee Pathology/Neuropathology for the validation of examination methods in Molecular Pathology 71 SD 4 037 Revision: 1.1 04 October 2016 Scope of application: This guideline
More informationValidation of Laboratory-Developed Molecular Assays for Infectious Diseases
CLINICAL MICROBIOLOGY REVIEWS, July 2010, p. 550 576 Vol. 23, No. 3 0893-8512/10/$12.00 doi:10.1128/cmr.00074-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Validation of Laboratory-Developed
More informationDiagnostics in Oncology Mark Kockx MD, PhD
HistoGeneX The Real World A Specialized of companion Biomarker & Integrated Pathology Laboratory Diagnostics in Oncology Mark Kockx MD, PhD 1 2 HistoGeneX located in Antwerp, Belgium and Chicago, Illinois
More informationvalidation report for TaqMan Roundup Ready Quantification Kit
validation report for TaqMan Roundup Ready Quantification Kit Life Technologies offers a breadth of products DNA RNA protein cell culture instruments For Research Use Only. Not intended for any animal
More informationPage 1. AMPTask Force on MLS Molecular Pathology Curriculum Dear Molecular Diagnostics Laboratory Manager,
AMPTask Force on MLS Molecular Pathology Curriculum Dear Molecular Diagnostics Laboratory Manager, Recently the Association for Molecular Pathology (AMP) has decided to develop a suggested curriculum in
More informationMolecular Diagnostics
Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R
More informationBioresearch Monitoring Inspections in Vitro Diagnostics Devices
Seite 1 von 7 U.S. Food and Drug Administration Protecting and Promoting Your Health Bioresearch Monitoring Inspections in Vitro Diagnostics Devices TABLE OF CONTENTS Introduction Nature, Scope, & Purpose
More informationLaboratory Accreditation Test Validation: A Brave New World for Anatomic Pathology
Laboratory Accreditation Test Validation: A Brave New World for Anatomic Pathology Francis E. Sharkey, MD, FCAP University of Texas Health Science Center, San Antonio, TX Richard W. Brown, MD, FCAP Memorial
More informationGuidance for Industry and FDA Staff. Replacement Reagent and Instrument Family Policy
Guidance for Industry and FDA Staff Replacement Reagent and Instrument Family Policy Document issued on: December 11, 2003 This document supersedes Data for Commercialization of Original Equipment Manufacturers
More information510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: k100499 B. Purpose for Submission: New Device C. Measurand: Rheumatoid Factors IgG, IgM and IgA and Rheumatoid
More information2009 LAP Audioconference Series. Accreditation Requirements in Molecular Pathology
2009 LAP Audioconference Series Accreditation Requirements in Molecular Pathology Objectives: After participating in this audioconference, you will be able to: Describe the process of analytical and clinical
More informationLabGuide 13 How to Verify Performance Specifications
1 LG 13 Comments? Feedback? Questions? Email us at info@cola.org or call us at 800 981-9883 LabGuide 13 How to Verify Performance Specifications The verification of performance specifications confirms
More informationA Risk-based Approach for In Vitro Companion Diagnostics Device FDA Approval Process Associated with Therapies that have Breakthrough Designation
A Risk-based Approach for In Vitro Companion Diagnostics Device FDA Approval Process Associated with Therapies that have Breakthrough Designation A Risk-based Approach for In Vitro Companion Diagnostics
More informationFrequently Asked Questions
This image cannot currently be displayed. HSV 1+2 Frequently Asked Questions General How reproducible is the AmpliVue HSV 1+2 Assay? The reproducibility of the AmpliVue HSV 1+2 Assay was evaluated at three
More informationMM12-A ISBN Volume 26 Number 20 ISSN Diagnostic Nucleic Acid Microarrays; Approved Guideline
ISBN 1-56238-608-5 Number 20 ISSN 0273-3099 Diagnostic Nucleic Acid Microarrays; Approved Guideline Joseph L. Hackett, PhD Kellie J. Archer, PhD Adolfas K. Gaigalas, PhD Carleton T. Garrett, MD, PhD Loren
More informationCASE-STUDY- VALIDATION of PCR based methodology. Beata Surmacz-Cordle Senior Analytical Development Scientist
CASE-STUDY- VALIDATION of PCR based methodology Beata Surmacz-Cordle Senior Analytical Development Scientist UK RMP Pluripotent Stem Cell Platform Validation Workshop 2 nd June 2016 RT-qPCR assay for detection
More informationQUALITY CONTROL/QUALITY ASSURANCE IN THE MOLECULAR MICROBIOLOGY LABORATORY
QUALITY CONTROL/QUALITY ASSURANCE IN THE MOLECULAR MICROBIOLOGY LABORATORY Richard L. Hodinka, Ph.D. University of South Carolina School of Medicine Greenville Greenville Health System, Greenville, SC
More informationRole of the WHO IVD Prequalification Programme in Light of National Regulatory Authority Approval
Role of the WHO IVD Prequalification Programme in Light of National Regulatory Authority Approval UN Prequalification of Medicines, Diagnostics and Vaccines 6 th Consultative Stakeholder Meeting 4 April
More informationGuidance for Industry and FDA Staff Pharmacogenetic Tests and Genetic Tests for Heritable Markers
Guidance for Industry and FDA Staff Pharmacogenetic Tests and Genetic Tests for Heritable Markers Document issued on: June 19, 2007 The draft of this guidance was issued on February 9, 2006 U.S. Department
More informationRegulatory Perspective for Companion Diagnostics
Regulatory Perspective for Companion Diagnostics The 38 th Annual Midwest Biopharmaceutical Statistical Workshop (MBSW) May 19, 2015 Jennifer Shen, Ph.D., RAC Food and Drug Administration (FDA) Center
More informationFirst Annual Biomarker Symposium Quest Diagnostics Clinical Trials
First Annual Biomarker Symposium Quest Diagnostics Clinical Trials Terry Robins, Ph.D. Director Biomarker R&D and Scientific Affairs Quest Diagnostics Clinical Trials Key Considerations: Biomarker Development
More informationA New Era of Clinical Diagnostics: How the Business Model is Changing.
A New Era of Clinical Diagnostics: How the Business Model is Changing. Nancy J Kelley, President and CEO of Nancy J Kelley & Associates Remarks to BTIG Emerging Technologies in Healthcare Diagnostics September
More informationMolecular Diagnostics In Jordan
Molecular Diagnostics In Jordan ASTF forum Amman, March 2008 Dr. Said Ismail د. سعيد إسماعيل Faculty of Medicine آلية الطب / الجامعة الا ردنية University of Jordan Outline: 1. Introduction 2. Techniques
More informationQC and Reference Material for Genetic Testing US Regulatory Aspects
QC and Reference Material for Genetic Testing US Regulatory Aspects Zivana Tezak, Ph.D. Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) Center for Devices and Radiological Health, FDA
More informationTECHNICAL GUIDANCE FOR THE VALIDATION OF METHODS USED BY CHEMICAL LABORATORIES IN THE FOOD, WATER AND RELATED INDUSTRIES
TECHNICAL GUIDANCE FOR THE VALIDATION OF METHODS USED BY CHEMICAL LABORATORIES IN THE FOOD, WATER AND RELATED INDUSTRIES Approved By: Chief Executive Officer: Ron Josias Senior Manager: Christinah Leballo
More informationMedical Devices; Immunology and Microbiology Devices; Classification of the Next Generation
This document is scheduled to be published in the Federal Register on 06/22/2018 and available online at https://federalregister.gov/d/2018-13406, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationThe Centers for Disease Control NSMBB Molecular Assessment Program (MAP): Evaluation of Newborn Screening Molecular Testing.
The Centers for Disease Control NSMBB Molecular Assessment Program (MAP): Evaluation of Newborn Screening Molecular Testing. Newborn screening (NBS) is the process of testing infants for serious developmental,
More informationBest Practices for the Use of International Standards in Vaccine Testing Dianna Wilkinson
Best Practices for the Use of International Standards in Vaccine Testing Dianna Wilkinson DCVMN Regional Training Workshop Hyderabad, 07-10 May, 2018 Biologicals substances which cannot be fully characterized
More informationReady, Set, Test! AACC Conference Mass Spectrometry in the Clinical Lab: Best Practice and Current Applications September 17-18, 2013 St.
Ready, Set, Test! Ross Molinaro, PhD, MLS(ASCP) CM, DABCC, FACB Medical Director, Clinical Laboratories Emory University Hospital Midtown Emory Clinical Translational Research Laboratory AACC Conference
More informationWAIT! Ready, Set, Test! Financial Disclosure. Research/Educational grants/consulting/salary support
Ready, Set, Test! Ross Molinaro, PhD, MLS(ASCP) CM, DABCC, FACB Medical Director, Clinical Laboratories Emory University Hospital Midtown Emory Clinical Translational Research Laboratory AACC Conference
More informationFDA's Initiative to Regulate Lab- Developed Tests (LDT) will Harm Patients and Academic Pathology
FDA's Initiative to Regulate Lab- Developed Tests (LDT) will Harm Patients and Academic Pathology Edward Ashwood President and CEO, ARUP Laboratories Tenured Professor of Pathology, University of Utah
More informationESCMID Online Lecture Library. by author
Molecular diagnostics: when to use (commercial vs in house) Marijke Raymaekers (Belgium) Kate Templeton (UK) Are you mainly using home-brew or commercial assays? In house diagnostics home brew assays Commercial
More informationDeveloping an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL
Developing an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL James Storhoff, Ph.D. Senior Manager, Diagnostic Test Development World Cdx, Boston, Sep. 10th Molecules That
More informationSummary of key processes for tumor BRCA testing. Q&A Session Hadassah Medical Center, Jerusalem Sabine Merkelbach-Bruse
Summary of key processes for tumor BRCA testing Q&A Session 29.01.2018 Hadassah Medical Center, Jerusalem Sabine Merkelbach-Bruse Review of key processes Overview Summary of key processes Quality assurance
More informationQuantStudio Dx Real-Time PCR Instrument
QuantStudio Dx Real-Time PCR Instrument Behind every diagnosis, there is a promise You believe in molecular medicine. So do we. We are committed to providing you with comprehensive solutions that help
More informationExecutive Summary. clinical supply services
clinical supply services case study Development and NDA-level validation of quantitative polymerase chain reaction (qpcr) procedure for detection and quantification of residual E.coli genomic DNA Executive
More informationPROPOSED FINAL DOCUMENT
AHWP/WG1a/PF004:2013 PROPOSED FINAL DOCUMENT Title: Author: Comparison between the GHTF Summary Technical Documentation (STED) formats for Medical Devices and In Vitro Diagnostic Medical Devices and the
More informationTechnical Guidance on Development of In Vitro Companion Diagnostics and Corresponding Therapeutic Products
Administrative Notice December 26, 2013 To: Division of Pharmaceutical Affairs, Prefectural Health Department (Bureau) From: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry
More informationSAMPLE. Quantitative Molecular Methods for Infectious Diseases; Approved Guideline Second Edition
November 2010 Quantitative Molecular Methods for Infectious Diseases; Approved Guideline Second Edition This document provides guidance for the development and use of quantitative molecular methods, such
More informationSpecific Accreditation Criteria
Specific Accreditation Criteria ISO/IEC 17025 Application Document Materials - Annex Characterisation of industrial materials - General July 2018 Copyright National Association of Testing Authorities,
More informationCRITERIA FOR VALIDATION OF METHODS USED BY CHEMICAL LABORATORIES AND RELATED INDUSTRIES
Document No: SADCAS TR 17 Issue No: 1 CRITERIA FOR VALIDATION OF METHODS USED BY CHEMICAL LABORATORIES AND RELATED INDUSTRIES Prepared by: SADCAS Advisory Committee TLAP Approved by: SADCAS CEO Approval
More informationBioRobot EZ1 DSP Walkaway Nucleic Acid Purification for Molecular Diagnostics
BioRobot EZ1 DSP Walkaway Nucleic Acid Purification for Molecular Diagnostics CE-IVD-marked system Sample & Assay Technologies Fully automated CE-IVD-compliant solution The BioRobot EZ1 DSP system enables
More informationThe In Vitro Diagnostic CRO
The In Vitro Diagnostic CRO Choose Beaufort Because of Our People, Processes and Proven Experience The value of expertise cannot be overstated, especially when it comes to streamlining complicated in vitro
More informationValidation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals.
Validation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals. 1 Analytical Method Validation: 1..1 Philosophy: Method validation is
More informationCommon Issues in Qualification and Validation of Analytical Procedures
Common Issues in Qualification and Validation of Analytical Procedures Alexey Khrenov, PhD OTAT/CBER/FDA CMC Strategy Forum January 29, 2018 - Washington, DC Disclaimer These comments are an informal communication
More information23andMe Personal Genome Service (PGS) Genetic Health Risk Report Package Insert BRCA1/BRCA2 (Selected Variants)
23andMe Personal Genome Service (PGS) Genetic Health Risk Report Package Insert /BRCA2 (Selected Variants) Table of contents Indications for use Summary and explanation of the test Important considerations
More informationA2LA. R231 Specific Requirements: Threat Agent Testing Laboratory Accreditation Program. December 6, 2017
Laboratory Page 1 of 17 Laboratory December 6, 2017 2017 by A2LA All rights reserved. No part of this document may be reproduced in any form or by any means without the prior written permission of A2LA.
More informationStart With the End in Mind A Diagnostic Company s Perspective on Companion Diagnostic Development. Paul Docherty PhD Relationship Management
Start With the End in Mind A Diagnostic Company s Perspective on Companion Diagnostic Development Paul Docherty PhD Relationship Management Disclaimer This presentation contains my personal views and research
More informationDedicated to Molecular Diagnostics
Dedicated to Molecular Diagnostics For Europe Sample & Assay Technologies QIAGEN s growing role in molecular diagnostics At QIAGEN, one of our key goals is to support clinical decision-making and improve
More informationThe steps involved in test validation are meant to answer
CAP Laboratory Improvement Programs Recommended Principles and Practices for Validating Clinical Molecular Pathology Tests Lawrence Jennings, MD, PhD; Vivianna M. Van Deerlin, MD, PhD; Margaret L. Gulley,
More informationWhat is the purpose of this website?
What is the purpose of this website? This website aims to explain: How it is possible for different methods to give different results for the same test on the same patient sample Why it is important to
More informationMolecular Diagnostics Regulation Shifting from a Biomarker-Based Approach to an Algorithm-Based Approach
Molecular Diagnostics Regulation Shifting from a Biomarker-Based Approach to an Algorithm-Based Approach Presented by Kathryn Scheckel Co-authored with Gary Marchant May 27, 2015 Molecular Diagnostics
More informationDisclosures. Laboratory Stakeholders. IVD vs. LDT. FDA Regulation of Laboratory Developed Tests 10/2/2015. FDA Regulation of LDTs
Disclosures FDA Regulation of Laboratory Developed Tests Beaumont Health System, 24 th Annual Symposium on Molecular Pathology September 16, 2015 Roger D. Klein, MD JD Director, Molecular Pathology Clinical
More informationMegan Schmidt Vice President of Product Management, CompuGroup Medical
Thursday April 6, 2017 A01 Molecular and Genetic Testing: How to Position your Laboratory for New Technology Megan Schmidt Vice President of Product Management, CompuGroup Medical DESCRIPTION: Molecular
More informationPOLYMERASE CHAIN REACTION (PCR) TECHNOLOGIES AND GLOBAL MARKETS
POLYMERASE CHAIN REACTION (PCR) TECHNOLOGIES AND GLOBAL MARKETS BIO087B March 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-742-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationDNA Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast,
DNA Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013-2019 The completion of human genome project resulted in discovery of several human disease causing genes.
More informationPerspective: Convergence of CLIA and FDA Requirements A Rational Shift in the Regulatory Paradigm
Perspective: Convergence of CLIA and FDA Requirements A Rational Shift in the Regulatory Paradigm Planning for Efficiencies of Data, Resources, and Timelines A PRECISION BRIEF Introduction As precision
More informationCulture Vs. qpcr. Daniel Grandio Gonzalez
Culture Vs. qpcr Daniel Grandio Gonzalez Introduction Legionelosis, Pontiac Fever, Mycobacteriosis Legionella: Hot water tanks, showers, cooling towers, swimming pools Environmental Mycobacteria: Purified
More informationQPCR ASSAYS FOR MIRNA EXPRESSION PROFILING
TECH NOTE 4320 Forest Park Ave Suite 303 Saint Louis, MO 63108 +1 (314) 833-9764 mirna qpcr ASSAYS - powered by NAWGEN Our mirna qpcr Assays were developed by mirna experts at Nawgen to improve upon previously
More informationTargeted Sequencing in the NBS Laboratory
Targeted Sequencing in the NBS Laboratory Christopher Greene, PhD Newborn Screening and Molecular Biology Branch Division of Laboratory Sciences Gene Sequencing in Public Health Newborn Screening February
More informationBest Practices for the Use of International Standards in Vaccine Testing Dianna Wilkinson
Best Practices for the Use of International Standards in Vaccine Testing Dianna Wilkinson DCVMN Regional Training Workshop Hyderabad, 07-10 May, 2018 Biologicals substances which cannot be fully characterized
More informationQuest Diagnostics and QIAGEN Relationship. Michael A. Lewinski, Ph.D., D(ABMM) Director, Infectious Diseases Quest Diagnostics Nichols Institute
QIAGEN Presents: An Investor/Analyst Event Quest Diagnostics and QIAGEN Relationship Michael A. Lewinski, Ph.D., D(ABMM) Director, Infectious Diseases Quest Diagnostics Nichols Institute Objectives Who
More informationREPEATABILITY, REPRODUCIBILITY AND ANALYTIC STANDARDS FOR BIOMARKER DEVELOPMENT
REPEATABILITY, REPRODUCIBILITY AND ANALYTIC STANDARDS FOR BIOMARKER DEVELOPMENT ABBAS BANDUKWALA BIOMARKER QUALIFICATION PROGRAM ABBAS.BANDUKWALA@FDA.HHS.GOV May 17, 2018 1 Disclaimer This presentation
More informationLATE-PCR. Linear-After-The-Exponential
LATE-PCR Linear-After-The-Exponential A Patented Invention of the Laboratory of Human Genetics and Reproductive Biology Lab. Director: Lawrence J. Wangh, Ph.D. Department of Biology, Brandeis University,
More informationValidating, Verifying, and Evaluating Your Test Methods: It s NOT a Regulatory Exercise!
Validating, Verifying, and Evaluating Your Test Methods: It s NOT a Regulatory Exercise! Pat Garrett, Ph.D., DABCC Renee Howell, Ph.D., MT(ASCP) SeraCare Life Sciences, Inc. AACC Annual Meeting July 29,
More informationLDT Review: The New York Experience
LDT Review: The New York Experience APHL Meeting, Indianapolis, May 21, 2015 Erasmus Schneider, Wadsworth Center, NYS DOH erasmus.schneider@health.ny.gov May 21, 2015 May 21, 2015 2 As the New York State
More informationMolecular Diagnostics
Molecular Diagnostics Positioning the Laboratory for the Future Through Scalable Lab Developed Test Workflows, Clinical-level Quality, & Operational Efficiency Path to the heart of healthcare Change It
More informationWhat is an LDT? The Do s s And Don ts of Validating Laboratory Developed Tests
The Do s s And Don ts of Validating Laboratory Developed Tests Deirdre Astin, MS, MT (ASCP) Lab Quality Confab 2011 November 2011 San Antonio Texas What is an LDT? Laboratory developed tests (LDTs) are
More informationEvent-specific Method for the Quantification of Soybean CV127 Using Real-time PCR. Validation Report
Event-specific Method for the Quantification of Soybean CV127 Using Real-time PCR Validation Report 20 September 2011 Joint Research Centre Institute for Health and Consumer Protection Molecular Biology
More informationHow to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations. The complete guide to developing or expanding your lab
How to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations The complete guide to developing or expanding your lab Includes step-by-step plans for basic and full-service MDx
More informationi) Wild animals: Those animals that do not live under human supervision or control and do not have their phenotype selected by humans.
The OIE Validation Recommendations provide detailed information and examples in support of the OIE Validation Standard that is published as Chapter 1.1.6 of the Terrestrial Manual, or Chapter 1.1.2 of
More informationAssay Validation Services
Overview PierianDx s assay validation services bring clinical genomic tests to market more rapidly through experimental design, sample requirements, analytical pipeline optimization, and criteria tuning.
More informationRegulatory Overview of Proposed LDT Framework. FDA Concerns. Background. FDA Proposed Regulatory Approach. By Ben Berg, Meaghan Bailey, RAC
Regulatory Overview of Proposed LDT Framework By Ben Berg, Meaghan Bailey, RAC On July 31, 2014, the U.S. Food and Drug Administration (FDA or the Agency) notified both the Senate Committee on Health,
More informationMedical Devices; Exemption From Premarket Notification; Class II Devices; Autosomal
This document is scheduled to be published in the Federal Register on 11/07/2017 and available online at https://federalregister.gov/d/2017-24162, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationOversight of Laboratory Developed Tests
Oversight of Laboratory Developed Tests APHL Annual Meeting 2015 Indianapolis Alberto Gutierrez, PhD Office of In Vitro Diagnostics and Radiological Health 1 Overview Background IVD regulation Need for
More informationStrep Assay. Frequently Asked Questions
Strep Assay Frequently Asked Questions General What is the sensitivity/specificity of the Lyra Direct Strep Assay? Performance characteristics of the Lyra Direct Strep Assay using the Applied Biosystems
More informationBiosensor: Design and Analytical evaluation
Biosensor: Design and Analytical evaluation. 2015-02-13 How to proceed in biosensor design? 1) Identify the analyte Which biorecognition element can I use (enzyme; antibodies..)? In which matrix will I
More informationComments from the FDA Working Group on SUBGROUP ANALYSES. Estelle Russek-Cohen, Ph.D. U.S. Food and Drug Administration Center for Biologics
Comments from the FDA Working Group on SUBGROUP ANALYSES Estelle Russek-Cohen, Ph.D. U.S. Food and Drug Administration Center for Biologics 1 Outline An intro to FDA EMA and FDA on subgroups Companion
More informationAccessible answers. Targeted sequencing: accelerating and amplifying answers for oncology research
Accessible answers Targeted sequencing: accelerating and amplifying answers for oncology research Help advance precision medicine Accelerate results with Ion Torrent NGS Life without cancer. This is our
More informationOverview of the FDA Approval Process for TB Diagnostics
Overview of the FDA Approval Process for TB Diagnostics Steven Gitterman, M.D., Ph.D. Division of Microbiology Devices Center for Devices and Radiological Health FDA Definition: In Vitro Diagnostic Device
More informationHELINI Hepatitis B virus [HBV] Real-time PCR Kit (Genotype A to H)
HELINI Hepatitis B virus [HBV] Real-time PCR Kit (Genotype A to H) Quantitative In vitro diagnostics Instruction manual Cat. No: 8001-25/50/100 tests Compatible with: Agilent, Bio-Rad, Applied Bio systems
More informationWhat is? An Overview of Operational Processes
Friday April 7, 2017 LD4 What is? An Overview of Operational Processes John T. Daly, MD, FCAP Chief Medical Officer, COLA DESCRIPTION: This session focuses on other important topics for the laboratory
More informationFrom Liquid Biopsy and FFPE Samples to Results
From Liquid Biopsy and FFPE Samples to Results Fully automated purification, reliable quantification and bisulfite conversion of cell-free circulating DNA and DNA from FFPE samples Fully automated purification,
More informationStandardisation of real-time PCR. Dr P. Lewis White Public Health Wales
Standardisation of real-time PCR Dr P. Lewis White Public Health Wales The MIQE Guidelines Publications reporting real-time PCR are ubiquitous Lack of sufficient experimental detail Limits the potential
More informationEvent-specific Method for the Quantification of Maize Line MON Using Real-time PCR. Validation Report
Event-specific Method for the Quantification of Maize Line MON 88017 Using Real-time PCR Validation Report 30 March 2010 Joint Research Centre Institute for Health and Consumer Protection Molecular Biology
More informationHBV Quantitative & YMDD Mutation Real Time PCR Kit
Revision No.: ZJ0002 Issue Date: Aug 7 th, 2008 HBV Quantitative & YMDD Mutation Real Time PCR Kit Cat. No.: HD-0003-01 For Use with LightCycler 1.0/LightCycler2.0/LightCycler480 (Roche) Real Time PCR
More informationFrom Liquid Biopsy and FFPE Samples to Results
www.autogen.com 774-233-3000 From Liquid Biopsy and FFPE Samples to Results Fully automated purification, reliable quantification and bisulfite conversion of cell-free circulating DNA and DNA from FFPE
More information